Fate Therapeutics (FATE) came out with a quarterly loss of $0.47 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this clinical-stage biotech company that develops stem cell treatments would post a loss of $0.57 per share when it actually produced a loss of $0.45, delivering a surprise of 21.05%.Over the last four quarters, the company has surpassed consensus EPS es ...

Financial Performance - The company has incurred net losses since its inception in 2007, with significant losses expected to continue in the foreseeable future[112]. - The company had an accumulated deficit of $1.3 billion as of March 31, 2024, and anticipates continued net losses[143]. - Cash used in operating activities increased to $33.4 million in Q1 2024 from $28.9 million in Q1 2023, driven by a higher net loss[144]. - Other income (expense), net was $3.1 million in Q1 2024, down from $9.7 million in Q1 2023, impacted by changes in fair value of stock price appreciation milestones[141]. Collaboration Revenue - Collaboration revenue for the three months ended March 31, 2024, was $1.9 million, a decrease from $6.7 million in the same period in 2023[123]. - The company recognized $52.3 million of collaboration revenue under the Janssen Agreement during the three months ended March 31, 2023[127]. - Collaboration revenue decreased to $1.9 million in Q1 2024 from $59.0 million in Q1 2023, primarily due to the termination of the Janssen contract[139]. Research and Development - Research and development expenses include costs related to the development of product candidates and are expected to remain significant as the company continues its activities[128]. - The company plans to invest significantly in research and development activities over the next twelve months, focusing on clinical and preclinical development[129]. - Research and development expenses were $32.1 million in Q1 2024, down from $65.6 million in Q1 2023, reflecting a decrease in clinical trial and consulting expenses[140]. - The company has a deep pipeline of iPSC-derived CAR-targeted NK and T-cell product candidates currently under development with multiple clinical trials ongoing[109]. - The company has entered into collaborations with academic institutions and pharmaceutical companies to support the development of its iPSC product platform[109]. Cash Flow and Financing - Investing activities provided cash of $17.3 million in Q1 2024, compared to $9.3 million in Q1 2023, due to increased net maturities of investments[145]. - Financing activities generated $95.5 million in Q1 2024, primarily from the issuance of 14,545,454 shares at $5.50 per share[146]. - As of March 31, 2024, the company had cash and cash equivalents of $391.1 million, sufficient to fund projected operating requirements for at least the next twelve months[148]. - The company anticipates needing additional capital for research, manufacturing, and development of product candidates due to potential changes in business conditions and global economic factors[154]. Obligations and Risks - The company has a milestone payment obligation to MSKCC totaling up to $75 million, with a recent payment of $20 million made after achieving a specified clinical milestone[159]. - The company may need to adjust its business operations if it cannot secure sufficient capital, which could materially affect its financial condition and prospects[157]. - The company has no material contractual obligations not fully recorded on its balance sheets or disclosed in financial statement notes[160]. - Inflation rates and global political conditions, including conflicts, are being closely monitored as they may negatively impact the company's financial condition and operational results[156]. - Inflation has persisted and may continue to rise, potentially affecting operating results, although no material impact has been observed to date[161]. - The company may face challenges in raising additional capital on reasonable terms, which could lead to delays or discontinuation of product development[154]. Operational Considerations - The company is evaluating the costs and timing of clinical trials and regulatory approvals, which are critical for its product candidates[156]. - Future funding requirements will depend on various factors, including the progress and costs associated with clinical trials and manufacturing activities[155]. - The company is assessing its operating capital requirements and may make necessary adjustments to its business operations[156].

Exhibit 99.1 Enrollment Initiated with FT522 CAR NK Cell Product Candidate in Conditioning-free Treatment Arm of Phase 1 B Cell Lymphoma Study First Patient Treated with FT825 / ONO-8250 CAR T-cell Product Candidate in Phase 1 Solid Tumor Study $391 Million in Cash, Cash Equivalents, and Investments San Diego, CA – May 9, 2024 – Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived ce ...

Pre-treatment Sample of Patient's Blood Showed Rapid and Potent Depletion of CD19+ B Cells in Ex Vivo Cytotoxicity Assay with FT819 Translational Data from FT819 Phase 1 B Cell Malignancies Study Support Key Therapeutic Mechanisms of Activity for B Cell-mediated Autoimmune Diseases Initial Clinical Observations of FT522 CAR NK Cell Program in Phase 1 B Cell Lymphoma Study Show Rapid, Deep, and Sustained B Cell Depletion and Enhanced Persistence in the Periphery SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Fa ...

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, will host a conference call and live audio webcast on Thursday, May 9, 2024 at 5:00 PM ET to report its first quarter 2024 financial results and highlight operational updates, i ...

Off-the-shelf, CD19-targeted CAR NK Cell Product Candidate Drives Rapid and Deep Depletion of SLE Donor CD19+ B cells ADR Technology Incorporated into FT522 Induces Functional Persistence and Eliminates Alloreactive Host Immune Cells in SLE Donor PBMCs SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients ...

Fate Therapeutics’ (FATE) shares have surged 86.4% year to date compared with the industry’s growth of 1.5%. This can be attributed to the overall positive sentiment across the company’s innovative pipeline and recent pipeline progress.FATE is a clinical-stage biopharmaceutical company, building a pipeline of programmed cellular immunotherapies for cancer and autoimmune diseases. The company is using cell programming to create better cell therapies. It creates and engineers human induced pluripotent stem ce ...

SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced the pricing of an underwritten offering of 14,545,454 shares of its common stock at an offering price of $5.50 per share. The offering includes participation ...

SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company granted a non-qualified stock option to one newly-hired employee to purchase a total of 40,000 shares of the Company's common stock at an exercise price per share of $7.74, which w ...

SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences: TD Cowen's 44th Annual Health Care Conference on Wednesday, March 6th, 2024 ...